ZURA Stock — Zura Bio Limited Class A Ordinary Shares

Zura Bio Limited Class A Ordinary Shares (ZURA)

Updated October 16, 2026.

ZURA is a Stock. Total return is -52.5% over the past 3.6 years, 155.0 points behind SPY at 102.5%.

Zura Bio Limited is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory disorders, with a pipeline that includes Tibulizumab (in Phase 2 trials targeting IL-17A and BAFF), Torudokimab (completed Phase 1 for interleukin-33), and Crebankitug (completed Phase 1 for interleukin-7 receptor alpha). The company does not currently distribute income to shareholders. This security appeals to investors seeking exposure to early-stage biotech development with potential for significant gains if clinical candidates advance successfully, though it carries substantial research and development risk typical of pre-revenue stage companies.

ZURA performance versus SPY

Price and return data through 2026-10-16.

Total return is -52.5% over the past 3.6 years, 155.0 points behind SPY at 102.5%. Over the past year its total return — price change plus distributions reinvested — is 13.1%. Its deepest 1-year drawdown was 51.7%.

ZURA key facts

Asset type

Stock

Asset class

Equity

Inception date

03/20/2023

Distribution frequency

None

Last close

$3.88 (as of 2026-10-16)

Market cap

$371,817,052

Average volume

4881409.0

Beta

0.009

Payout ratio

0.0%

EPS

$-1.12

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ZURA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 51.7%.

Who may consider ZURA — and who may not

It is a weaker fit for investors who need monthly cash flow (ZURA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ZURA

• All tickers starting with Z

Tagged: Healthcare.

Frequently asked questions